vascular endothelial growth factor (VEGF) inhibitor
Jump to navigation
Jump to search
Indications
- VEGF inhibitors improve vision in diabetic macular edema[1]
- aflibercept may be most effective for worst baseline vision
- age-related macular degeneration[4]
- bevacizumab is used as an antineoplastic agent for metastatic colorectal cancer, lung cancer, ovarian cancer, breast cancer, malignant brain tumor, advanced cervical cancer, metastatic renal cell carcinoma
Dosage
- intravitreous administration
Adverse effects
Mechanism of action
- inhibits vascular endothelial growth factor (VEGF)
More general terms
More specific terms
- aflibercept (Eylea)
- bevacizumab (Avastin, Altuzan)
- brolucizumab; brolucizumab-dbll (Beovu)
- ranibizumab (Lucentis, Byooviz)
Additional terms
- vascular endothelial growth factor family protein (VEGF family)
- vascular endothelial growth factor [VEGF] receptor
References
- ↑ Jump up to: 1.0 1.1 The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351 - ↑ Usui J, Glezerman IG, Salvatore SP Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol. 2014 Sep;45(9):1918-27. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25087655
- ↑ Jump up to: 3.0 3.1 Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010 Nov;30(6):591-601. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21146124 Free PMC Article
- ↑ Jump up to: 4.0 4.1 Finger RP, Puth MT, Schmid M et al Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2020;138(12):1234-1240. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33057589 PMCID: PMC7563682 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2020.3989